1. Niu L, Geyer PE, Wewer Albrechtsen NJ, Gluud LL, Santos A, Doll S, et al. Plasma proteome profiling discovers novel proteins associated with non‐alcoholic fatty liver disease. Mol Syst Biol 2019;15(3):e8793. https://doi.org/10.15252/msb.20188793

2. Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med 2017;15(1):45. https://doi.org/10.1186/s12916-017-0806-8

3. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67(1):328-57. https://doi.org/10.1002/hep.29367

4. Povsic M, Wong OY, Perry R, Bottomley J. A structured literature review of the epidemiology and disease burden of non-alcoholic steatohepatitis (NASH). Adv Ther 2019;36(7):1574-94. https://doi.org/10.1007/s12325-019-00960-3

5. Huang T (Dazhong), Behary J, Zekry A. Non-alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management. Intern Med J 2020;50(9):1038-47. https://doi.org/10.1111/imj.14709

6. Paquissi FC. Immune Imbalances in Non-Alcoholic Fatty Liver Disease: From General Biomarkers and Neutrophils to Interleukin-17 Axis Activation and New Therapeutic Targets. Front Immunol 2016;7:490. https://doi.org/10.3389/fimmu.2016.00490

7. Hwang S, Yun H, Moon S, Cho YE, Gao B. Role of Neutrophils in the Pathogenesis of Nonalcoholic Steatohepatitis. Front Endocrinol 2021;12:751802. https://doi.org/10.3389/fendo.2021.751802

8. Chen Z, Tian R, She Z, Cai J, Li H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med 2020;20;152:116-41. https://doi.org/10.1016/j.freeradbiomed.2020.02.025

9. Bekheet IW, Madkour ME, Ghaffar NA, Nosseir MMF, Moussa MM, Ibraheim RA, et al. The Role of Myeloperoxidase in Hepatitis C Virus Infection and Associated Liver Cirrhosis. Open Trop Med J 2009;19;2(1):517-25. https://doi.org/10.4103/ijpm.ijpm_608_21

10. Chackelevicius CM, Gambaro SE, Tiribelli C, Rosso N. Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis. World J Gastroenterol 2016;22(41):9096-103. https://doi.org/10.3748/wjg.v22.i41.9096

11. Zhou Y, Zhang H, Zhang X, Guan Y, Zheng F. CD4+ T cell activation and inflammation in NASH-related fibrosis. Front Immunol 2022;13:967410. https://doi.org/10.3389/fimmu.2022.967410

12. Li Y, Jiang HT, Han LB, Xiao L, Gan JH. MiR-195 regulates CD40 to maintain Th17/Treg balance in rats with non-alcoholic fatty liver disease. Biomed Pharmacother 2020;124:109930. https://doi.org/10.1016/j.biopha.2020.109930

13. Xu R, Tao A, Zhang S, Zhang M. Neutralization of interleukin-17 attenuates high fat diet-induced non-alcoholic fatty liver disease in mice. Acta Biochim Biophys Sin 2013;45(9):726-33. https://doi.org/10.1093/abbs/gmt065

14. Harley ITW, Stankiewicz TE, Giles DA, Softic S, Flick LM, Cappelletti M, et al. IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice. Hepatology 2014;59(5):1830-9. https://doi.org/10.1002/hep.26746

15. Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic Steatohepatitis: A Review. JAMA 2020;323(12):1175-83. https://doi.org/10.1001/jama.2020.2298

16. Zhang YN, Fowler KJ, Hamilton G, Cui JY, Sy EZ, Balanay M, et al. Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging. Br J Radiol 2018;91(1089):20170959. https://doi.org/10.1259/bjr.20170959

17. Chao YL, Wu PY, Huang JC, Chiu YW, Lee JJ, Chen SC, et al. Hepatic Steatosis Is Associated with High White Blood Cell and Platelet Counts. Biomedicines 2022;10(4):892. https://doi.org/10.3390/biomedicines10040892

18. Forlano R, Mullish BH, Dhar A, Goldin RD, Thursz M, Manousou P. Liver function tests and metabolic-associated fatty liver disease: Changes in upper normal limits, does it really matter? World J Hepatol 2021;13(12):2104-12. https://doi.org/10.4254/wjh.v13.i12.2104

19. Sugiyama A, Kurisu A, E B, Ouoba S, Ko K, Rakhimov A, et al. Distribution of FIB-4 index in the general population: analysis of 75,666 residents who underwent health checkups. BMC Gastroenterol 2022;22(1):241. https://doi.org/10.1186/s12876-022-02290-1

20. Kim WR, Berg T, Asselah T, Flisiak R, Fung S, Gordon SC, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol 2016;64(4):773-80. https://doi.org/10.1016/j.jhep.2015.11.012

21. Duan Y, Luo J, Pan X, Wei J, Xiao X, Li J, et al. Association between inflammatory markers and non-alcoholic fatty liver disease in obese children. Front Public Health 2022;10:991393. https://doi.org/10.3389/fpubh.2022.991393

22. Shen T, Chen X, Li Y, Tang X, Jiang X, Yu C, et al. Interleukin-17A exacerbates high-fat diet-induced hepatic steatosis by inhibiting fatty acid β-oxidation. Biochim Biophys Acta Mol Basis Dis 2017;1863(6):1510-8. https://doi.org/10.1016/j.bbadis.2017.01.027

23. Amernia B, Moosavy SH, Banookh F, Zoghi G. FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran. BMC Gastroenterol 2021;21(1):453. https://doi.org/10.1186/s12876-021-02038-3

24. Dalbeni A, Castelli M, Zoncapè M, Minuz P, Sacerdoti D. Platelets in Non-alcoholic Fatty Liver Disease. Front Pharmacol 2022;13:842636. https://doi.org/10.3389/fphar.2022.842636

25. Juárez-Hernández E, Chávez-Tapia NC, Brizuela-Alcántara DC, Uribe M, Ramos-Ostos MH, Nuño-Lámbarri N. Association Between Serum Hemoglobin Levels and Non Alcoholic Fatty Liver Disease in a Mexican Population. Ann Hepatol 2018;17(4):577-84. https://doi.org/10.5604/01.3001.0012.0920

26. Hassan F, Farman M, Khan KA, Awais M, Akhtar S. Prevalence of nonalcoholic fatty liver disease in Pakistan: a systematic review and meta-analysis. Sci Rep 2024;14(1):19573. https://doi.org/10.1038/s41598-024-70481-9